Risk factors and incidence of venous thromboembolism in internal medicine: A prospective study on 947 in patients;Facteurs de risque et incidence de la maladie thromboembolique veineuse en médecine interne: Une étude descriptive prospective sur 947 patients hospitalisés

Revue de Medecine Interne

Volumn 22, Issue 4, 2001, Pages 348-359

  Pottier, P ^a   Planchon, B ^a   Pistorius, M A ^a   Grolleau, J Y ^a  

^a HÔTEL DIEU   (France)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Risk factor

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BED REST; FEMALE; HUMAN; HYPERCOAGULABILITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; VENOUS STASIS;

EID: 0035046233     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(01)00347-2     Document Type: Article

References (97)

1. The prevalence of risk factors for venous thromboembolism among hospital patients
2. Venous thromboembolism prophylaxis and risk assessment in medical patients
3. Deep vein thrombosis: Prevalence of etiologic factors and results of management in 100 consecutive patients
4. Prevalence of deep venous thrombosis among patients in medical intensive care
5. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly
6. Rationalisation des facteurs de risque de la maladie thromboembolique veineuse en milieu médical polyvalent hospitalier: Une étude prospective
7. Risk assessment of pulmonary embolism by multivariate analysis
8. Venous thromboembolism in stroke: Literature review and implications for clinical practice
9. Mortality factors in patients with acute strokes
10. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: A randomized pilot study (30 patients)
11. Deep venous thrombosis in high-risk hemiplegic patients: Detection by impedance plethysmography
12. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke
13. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients
14. Thromboembolism complications following acute hemiplegias
15. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke
16. Orgaran in the prevention of deep vein thrombosis in stroke patients
17. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study
18. Phlebothrombosis and pulmonary embolism in paraplegics
19. Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease
20. Venous thrombosis following strokes
21. Anticoagulant therapy in prevention of venous thrombosis and pulmonary embolism in spinal cord injury
22. Anticoagulant therapy in prevention of venous thrombosis and pulmonary embolism in the spinal cord injury
23. Anticoagulant therapy in the treatment of venous thrombosis and pulmonary embolism in acute spinal cord injury
24. Deep venous thrombosis in spinal cord injury. Overview of the problem
25. Clinically suspect pulmonary embolism after vein stripping
26. Smoking and risk factors in deep vein thrombosis
27. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis
28. Risk factors in pulmonary embolism
29. Anticoagulants in congestive heart failure
30. Heparin in the prevention of deep vein thrombosis after myocardial infarction
31. Frequency of deep venous thrombosis after myocardial infarction
32. The incidence of deep venous thrombosis in patients with an acute myocardial infarction treated with acenocoumarol or indobufen
33. Deep venous thrombosis and lupus anticoagulant. A case-control study
34. Low-dose heparin in the prevention of thrombotic complications following acute myocardial infarction
35. The C.O.B.H group Hypercoagulability state in patients with chronic obstructive pulmonary disease
36. Incidence of deep vein thrombosis in bedridden nonsurgical patients
37. Prevention of thromboembolism after spinal cord injury
38. Prevention of thromboembolism in spinal cord injury: Role of low molecular weight heparin
39. Prevention of thromboembolism after spinal cord injury using low-molecular weight heparin
40. Deep vein thrombosis in spinal cord injury: Effect of prophylaxis with calf compression, aspirin, dipyridamole
41. Venous thromboembolism in spinal cord injury patients
42. Prophylactic low dose heparin anticoagulant therapy in patients with spinal cord injuries: A retrospective study
43. Is chronic spinal cord injury associated with increased risk of venous thromboembolism?
44. Management of deep vein thrombosis in spinal cord injury
45. Deep thrombophlebitis in polycythemia and uterine fibromyoma
46. Pheochromocytoma, polycythemia, and venous thrombosis
47. Estrogen replacement therapy and the risk of venous thrombosis
48. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S
49. Estrogen and the risk of coagulopathy
50. For the GTH study group on natural inhibitors. Thrombotic risk of women with hereditary antithrombin III, protein C- and protein S-deficiency taking oral contraceptive medication
51. Prevention of thromboembolic disease in general surgery with enoxaparin
52. Thrombosis with low-estrogen oral contraceptives
53. Speculation about mortality trends from venous thromboembolic disease in England and Wales and their relation to the pattern of oral contraceptive usage
54. Oral contraceptives and venous thromboembolism: Findings in a large prospective study
55. Thrombophlebitis and pulmonary embolism as complications of pregnancy
56. Thromboembolism during pregnancy and the postpartum state
57. Deep venous thrombosis and pulmonary embolism in pregnancy
58. Deep venous thrombosis in pregnancy: Risk factors and possibilities for prevention
59. Déficit héréditaire en antithrombine III
60. Congenital antithrombin III deficiency: Insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation
61. Screening for inherited thrombotic disorders
62. Incidence of thromboembolism in association with congenital disorders in coagulation and fibrinolysis
63. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombine IIII, protein C, protein. S
64. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism
65. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study
66. Cost-effectiveness of prophylaxis in total hip replacement
67. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis
68. Probability of recurrence of thrombosis in patients with and without factor V leiden
69. Antiphospholipid antibodies, haemostatic variables and thrombosis. A survey of 144 patients
70. Coagulation activation and fibrinolytic imbalance in subjects with antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
71. Antiphospholipid syndrome: Five year follow-up
72. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
73. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphysms. The Leiden Thrombophilia Study (LETS)
74. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis
75. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
76. The efficacy and safety of oral anticoagulation in patients with cancer
77. The risk of deep venous thrombosis : A computerized epidemiologic approach
78. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
79. La maladie thrombo-embolique veineuse en milieu gériatrique. Intérět de son dépistage et de son traitement
80. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxapatin Medicine Study Group
81. Épidémiologie de la maladie veineuse thrombo-embolique en milieu gériatrique
82. Identification of patients at risk for deep vein thrombosis
83. Total knee arthroplasty in obese patients
84. Preoperative coagulation indices in patients with morbid obesity
85. Obesity: Is it really a risk factor in thrombophlebitis?
86. Perioperative risks and safety of surgery for severe obesity
87. The prevention of venous thromboembolism in Italy
88. Prevention of venous thromboembolism. European Consensus Statement, 1-5 November 1991, developed at Oakley Court Hotel, Windsor, UK
89. Prevention of venous thrombosis and pulmonary embolism
90. Risk of and prophylaxis for venous thromboembolism in hospital patients
91. Prophylaxie des thromboses veineuses postopératoires: Recommandations de l'Assistance publique - Hôpitaux de Paris
92. Prevention of venous thromboembolism
93. A comparison of enaoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
94. The venous thrombotic risk in non-surgical patients: Epidemiological data comparing a low molecular weight heparin fragment (enoxaparin) to placebo
95. Nadroparine calcique dans la prévention de la maladie thrombo-embolique chez le sujet âgé. Étude de la tolérance